Personalized medicine in lung cancer: what we need to know
Publication in refereed journal


香港中文大学研究人员 ( 现职)

莫树锦教授 (肿瘤学系)

全文

数位物件识别号 (DOI) http://dx.doi.org/10.1038/nrclinonc.2011.126

引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/72WOS source URL

其它资讯

摘要Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes involving ALK has set the stage for personalized medicine for lung cancer. Patients selected using biomarkers have benefited from the development of EGFR tyrosine kinase inhibitors and ALK inhibitors with considerable improvement in tumor control and survival. Four key areas of knowledge that are essential to the development of targeted therapy are discussed in this Review: knowing the target, knowing the biomarker, knowing the end point and knowing the mechanisms of resistance.

着者Mok TSK
期刊名称Nature Reviews Clinical Oncology
出版年份2011
月份11
日期1
卷号8
期次11
出版社Nature Publishing Group
页次661 - 668
国际标準期刊号1759-4774
电子国际标準期刊号1759-4782
语言英式英语

Web of Science 学科类别Oncology; ONCOLOGY